Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xoma Royalty Corporation (NQ: XOMA )

31.01 +0.81 (+2.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,185
Open 30.60
Bid (Size) 31.00 (1)
Ask (Size) 31.04 (2)
Prev. Close 30.20
Today's Range 30.33 - 31.06
52wk Range 14.33 - 33.78
Shares Outstanding 11,782,723
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
From XOMA Corporation
Via GlobeNewswire

Performance

YTD
+48.44%
+48.44%
1 Month
+5.08%
+5.08%
3 Month
+6.42%
+6.42%
6 Month
+21.61%
+21.61%
1 Year
+108.96%
+108.96%

More News

Read More
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
From XOMA Corporation
Via GlobeNewswire
Demystifying XOMA: Insights From 5 Analyst Reviews
Via Benzinga
Peeling Back The Layers: Exploring XOMA Through Analyst Insights
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For XOMA
Via Benzinga
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
XOMA Royalty to Present at Upcoming Investor Conferences in September
From XOMA Corporation
Via GlobeNewswire
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
Via Benzinga
Exposures Product Safety
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
From XOMA Corporation
Via GlobeNewswire
3 Crazy Good Stocks to Buy With $500 Right Now
Via InvestorPlace
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
From XOMA Corporation
Via GlobeNewswire
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
From XOMA Corporation
Via GlobeNewswire
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
From XOMA Corporation
Via GlobeNewswire
XOMA Corporation Announces Closing of Tender Offer
From XOMA Corporation
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
From Brodsky & Smith LLC
Via GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
From XOMA Corporation
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)
From Brodsky & Smith LLC
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.